2010 U.S. Estimated # # of Population of Diagnosed Diagnosed Census Cases in Cases in (N=308,745,538) CLFM U.S. (SEER) Population Conditions (Prevalence) (Prevalence) Breast Cancer 2,899,726 1616 (F) N=87,502 Breast Cancer *ACS Est: 9 (M) (1 out 1,000) N=8,594 Kidney Cancer 358,603 149 N=127,874 Lymphoma 530,919 220 Non-Hodgkins N=127,874 Esophageal 34,551 14 Cancer N=127,874 Lung Cancer 402,326 167 N=127,874 Bladder Cancer 571,518 237 N=127,874 Leukemia 302,800 125 N=127,874 Myeloma 83,367 35 N=127,874 Neurobehavioral 4.4% ADHD 145 Effects in population Myelodysplastic 11115 5 Syndrome Scleroderma 741 0 Female Infertility 1,500,000 17 Hepatic 30,000,000 1,243 Steatosis Miscarriage 1,000,000 11 Toxicity 26,000,000 538 Subtotals: NA 4,530 * - American Cancer Society Estimates Furthermore, there is a substantial uncertainty as to when the number of CLFMs will submit and be found eligible for services under this law for the following reasons: the speculative data from USMC, whether or not one or more of the conditions is a direct result of toxins from CL, whether or not they are currently receiving affordable care/treatment and whether or not the CLFM is aware of the benefits offered by this law. Utilizing the maximum number of diagnosed cases in the CLFM population by prevalence, identified in Table 4, VA projected a range (10%, 25%, 50%, & 100%) of the potential diagnosed cases in the CLFM population (see Table 5) that may submit and be found eligible for services under this law.
2010 U.S. Population Census (N=308,745,538) # of Diagnosed Cases in U.S. (SEER) (Prevalence) Estimated # of Diagnosed Cases in CLFM Population (Prevalence) Conditions Breast Cancer (F) N=87,502 2,899,726 1616 Breast Cancer (M) N=8,594 *ACS Est: (1 out 1,000) 9 Kidney Cancer N=127,874 358,603 149 Lymphoma Non-Hodgkins N=127,874 530,919 220 Esophageal Cancer N=127,874 34,551 14 Lung Cancer N=127,874 402,326 167 Bladder Cancer N=127,874 571,518 237 Leukemia N=127,874 302,800 125 Myeloma N=127,874 83,367 35 Neurobehavioral Effects 4.4% ADHD in population 145 Myelodysplastic Syndrome 11115 5 Scleroderma 741 0 Female Infertility 1,500,000 17 Hepatic Steatosis 30,000,000 1,243 Miscarriage 1,000,000 11 Toxicity 26,000,000 538 Subtotals: NA 4,530 * - American Cancer Society Estimates Furthermore, there is a substantial uncertainty as to when the number of CLFMs will submit and be found eligible for services under this law for the following reasons: the speculative data from USMC, whether or not one or more of the conditions is a direct result of toxins from CL, whether or not they are currently receiving affordable care/treatment and whether or not the CLFM is aware of the benefits offered by this law. Utilizing the maximum number of diagnosed cases in the CLFM population by prevalence, identified in Table 4, VA projected a range (10%, 25%, 50%, & 100%) of the potential diagnosed cases in the CLFM population (see Table 5) that may submit and be found eligible for services under this law.
RegMgmt_ImpactAnalysisAO79IF_20140905.docx